Comparative evaluation of effectiveness and safety of 92% lactic acid peel versus 35% glycolic acid peel in facial melasma and its impact on melasma quality of life score
DOI:
https://doi.org/10.71152/ajms.v16i6.4539Keywords:
Melasma; Glycolic acid; Lactic acid; Melasma area and severity index scoring; Melasma quality of life scoresAbstract
Background: Melasma is a prevalent acquired skin hyperpigmentation condition. This condition typically manifests on the face and can considerably impair an individual’s self-image and self-esteem. Consequently, patients may find themselves avoiding social interactions due to feelings of social embarrassment. Therefore, prompt treatment of melasma is essential in enhancing patients’ self-confidence.
Aims and Objectives: The objective is to evaluate the effectiveness and safety of 92% lactic acid (LA) peels in comparison to 35% glycolic acid (GA) for the treatment of melasma, as well as their impact on the quality of life related to melasma.
Materials and Methods: In this research, individuals with facial melasma were randomly divided into two groups, each comprising 20 participants. They underwent treatment with either a 92% LA peel or a 35% GA peel, administered at 3-week intervals over an 18-week duration. The results were evaluated 3 weeks after the last treatment session. Assessment methods utilized, including the Melasma Area and Severity Index (MASI) scoring and Melasma Quality of Life (MELASQOL) scores, to gauge treatment outcomes in both groups. Furthermore, any adverse effects were recorded.
Results: The results were statistically significant regarding the reduction in mean and percentage decrease of the MASI and MELASQOL scores in both groups when compared to baseline. However, no significant differences were observed between the two groups, and only minimal adverse effects were reported.
Conclusion: Both the 92% LA peel and the 35% GA peel have been shown to be effective and safe in reducing facial melasma, as well as enhancing MELASQOL scores, with comparable results observed in both treatment groups.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
